E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Advanced or metastatic breast cancer |
Vergevorderd of gemetastaseerd mammacarcinoom |
|
E.1.1.1 | Medical condition in easily understood language |
Advanced or metastatic breast cancer |
Vergevorderde of uitgezaaide borstkanker |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To prove that the RECAP test is capable of selecting advanced breast cancer patients sensitive for treatment with the PARP inhibitor talazoparib as measured by the PFS rate at 4 months. |
|
E.2.2 | Secondary objectives of the trial |
1. To determine overall response rate and overall survival among HRD tumors treated with talazoparib. 2. To explore differences in molecular aberrations in HR genes (e.g. BRCA1/2, PALB2) between HRD tumors that respond and those that do not respond to talazoparib. Moreover, to determine whether non-BRCA1/2 or BRCA1 promoter methylated HRD tumors respond differently to talazoparib than BRCA1/2 mutated HRD tumors. 3. To explore mechanisms of reversion of the HRD phenotype by comparing paired biopsies before treatment and upon progression on talazoparib. 4. To unravel resistance mechanisms by sequencing a DNA repair gene panel on circulating tumor DNA (ctDNA) pretreatment and at disease progression. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Age ≥18 years WHO performance status 0-2 Advanced breast cancer Patients must have (had) a high grade (Bloom & Richardson grade 3) ER positive (>10%) and HER2 negative primary breast cancer or a triple negative (ER/PR<10%, HER2 negative) primary breast cancer or breast cancer and a BRCA1 and/or BRCA2 germline mutation The site of the metastatic lesion (or primary tumor in case it is still in situ) should be easily amendable for biopsy. NB: lung metastases (high risk of hemato-thorax) and bone metastases (not suitable for RECAP test because calcifications interfere with experimental procedures) are excluded. Use of low molecular weight heparin (LMWH) should be interrupted shortly before biopsy is scheduled, unless this is not necessary according to local protocols or after consent of the intervention radiologist The tumor must be HRD, as identified by the RECAP test Maximum of four prior lines of chemotherapy for advanced disease; Patients who received platinum compounds are eligible if they have had at least a progression free interval of four months Measureable or evaluable disease according to RECIST 1.1 criteria (appendix 2) Life expectancy ≥ 3 months Hemoglobin ≥ 10 g/dL (6,2 mmol/L) and ANC of ≥ 1.5 x 109 /L Platelets >100 x 10e9/L and INR <1.5, unless platelet/INR values are not necessary according to local protocols or after consent of the intervention radiologist for that particular site of biopsy (e.g. biopsy of the skin) Bilirubin <1.5 ULN and both AST and ALT <5x ULN in case a liver biopsy is planned Renal function as defined by serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min (by Cockcroft-Gault formula); Written informed consent |
|
E.4 | Principal exclusion criteria |
Any psychological condition potentially hampering compliance with the study protocol Any treatment with investigational antitumor drugs within 28 days prior to receiving the first dose of investigational treatment; or within 21 days for standard chemotherapy; or within 14 days for weekly scheduled chemotherapeutic regimens or endocrine therapy Radiotherapy within the last four weeks prior to receiving the first dose of investigational treatment; except 1 or 2 x8 Gy for pain palliation, then seven days interval after the last radiation should be maintained Patients who have received a PARP inhibitor previously for advanced setting Known persistent (>4 weeks) ≥ Grade 2 toxicity from prior cancer therapy (except for alopecia grade 2) Symptomatic brain or leptomeningeal metastases. If adequately treated with resection and/or irradiation and patients are at least four weeks completely free of symptoms of these metastases without the use of corticosteroids, patients could be eligible if all other in- and exclusion criteria are obeyed |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The aim of the current study is to assess the predictive potential of the RECAP test for in vivo response to talazoparib treatment by investigating the percentage of patients with HRD breast tumors with PFS on talazoparib monotherapy of 4 months or longer. The main endpoint is thus the proportion of patients with PFS at 4 months (PFS4). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints are overall response rate (ORR), overall survival (OS) among patients with HRD tumors treated with talazoparib. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Two monthly until progressive disease |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |